Alemtuzumab, Dual Graft-versus-Host Disease Prophylaxis, and Lower CD3+T Cell Doses Equalize Rates of Acute and Chronic Graft-versus-Host Disease in Pediatric Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation with Matched Unrelated Donor Peripheral Blood Stem Cells or Bone Marrow Grafts
- Resource Type
- Article
- Source
- Transplantation and Cellular Therapy; 20240101, Issue: Preprints
- Subject
- Language
- ISSN
- 26666375; 26666367